

Product Name: JNJ-26854165 (Serdemetan)
Revision Date: 01/10/2021

## **Product Data Sheet**

# JNJ-26854165 (Serdemetan)

**Cat. No.:** A4204

CAS No.: 881202-45-5
Formula: C21H20N4


M.Wt: 328.41

**Synonyms:** JNJ 26854165

Target: Apoptosis

Pathway: p53

Storage: Store at -20°C



# Solvent & Solubility

insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	3.0450 mL	15.2249 mL	30.4497 mL
	5 mM	0.6090 mL	3.0450 mL	6.0899 mL
	10 mM	0.3045 mL	1.5225 mL	3.0450 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary P53 activato	r, blocking Mdm2-p53 interaction
---------------------------	----------------------------------

**Cell Viability Assay** 

Reacting conditions:

IC<sub>50</sub> & Target

# Cell Line: H460, A549 cells, and HMEC-1 endothelial cells Preparation method: The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

In Vitro

0.5, 1, 2.5, 5, 10, 25 and 50 µM; 48 h

	Applications:	After 48 h treatment, Serdemetan inhibited cell proliferation with IC50 values of		
		3.9 µM, and 8.7 µM for H460 cells and A549 cells, respectively. Moreover,		
		Serdemetan at 5 μM inhibited HMEC-1 endothelial cell migration.		
	Animal experiment			
In Vivo	Animal models:	H460 and A549 cells, injected in the right flank of nude mice were grown as tumor xenografts.		
	Dosage form:	50 mg/kg; p.o. twice a week, for 2 weeks		
	Applications:	Serdemetan treatment significantly enhanced radiation-induced growth delays in A549 and H460 xenograft tumors.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility of slightly differ with the theoretical value. This is caused by an experiment system error and it is normal.		

### **Product Citations**

1. Chen R, Zhou J, et al. "A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors." Biochemistry. 2017 Jun 27;56(25):3273-3282.PMID:28581721

See more customer validations on www.apexbt.com.

#### References

1. Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J. and Deutsch, E. (2011) Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 312, 209-218

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

## **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com













APE BIO



APE BIO